LEADER 05559nam 2201225z- 450 001 9910639997503321 005 20231214133050.0 010 $a3-0365-5728-8 035 $a(CKB)5470000001633378 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/95857 035 $a(EXLCZ)995470000001633378 100 $a20202301d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHigh-Energy Gamma-Ray Astronomy$eResults on Fundamental Questions after 30 Years of Ground-Based Observations 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (504 p.) 311 $a3-0365-5727-X 330 $aThis volume celebrates the 30th anniversary of the first very-high energy (VHE) gamma-ray Source detection: the Crab Nebula, observed by the pioneering ground-based Cherenkov telescope Whipple, at teraelectronvolts (TeV) energies, in 1989. As we entered a new era in TeV astronomy, with the imminent start of operations of the Cherenkov Telescope Array (CTA) and new facilities such as LHAASO and the proposed Southern Wide-Field Gamma-ray Observatory (SWGO), we conceived of this volume as a broad reflection on how far we have evolved in the astrophysics topics that dominated the field of TeV astronomy for much of recent history.In the past two decades, H.E.S.S., MAGIC and VERITAS pushed the field of TeV astronomy, consolidating the field of TeV astrophysics, from few to hundreds of TeV emitters. Today, this is a mature field, covering almost every topic of modern astrophysics. TeV astrophysics is also at the center of the multi-messenger astrophysics revolution, as the extreme photon energies involved provide an effective probe in cosmic-ray acceleration, propagation and interaction, in dark matter and exotic physics searches. The improvement that CTA will carry forward and the fact that CTA will operate as the first open observatory in the field, mean that gamma-ray astronomy is about to enter a new precision and productive era.This book aims to serve as an introduction to the field and its state of the art, presenting a series of authoritative reviews on a broad range of topics in which TeV astronomy provided essential contributions, and where some of the most relevant questions for future research lie. 517 $aHigh-Energy Gamma-Ray Astronomy 606 $aResearch & information: general$2bicssc 606 $aMathematics & science$2bicssc 610 $agamma ray astronomy 610 $aimaging atmospheric Cherenkov technique 610 $aTeV gamma-rays 610 $anon-thermal radiation 610 $akeV-TeV cosmic sources 610 $aINTEGRAL legacy data base 610 $arelativistic astrophysics 610 $agamma rays 610 $acosmic rays 610 $ainterstellar medium 610 $aMilky Way 610 $agalaxies 610 $aradiation mechanisms: non-thermal 610 $ahigh energy astrophysics 610 $abackground radiation 610 $aphoton-photon interaction 610 $apair production 610 $aaxion-like particles 610 $agamma-rays 610 $aIACTs 610 $aintergalactic magnetic fields 610 $ahigh-energy gamma rays 610 $aelectromagnetic cascades 610 $apevatrons 610 $aGalactic cosmic rays 610 $aPeVatron 610 $aCrab Nebula 610 $aangular resolution 610 $aenergy spectral distribution 610 $a?-ray astronomy 610 $avery-high-energy gamma-ray astrophysics 610 $aastroparticle physics 610 $aimaging atmospheric Cherenkov telescopes 610 $aQuantum Gravity 610 $aLorentz invariance violation 610 $atime of flight 610 $amodified photon interactions 610 $avery-high-energy gamma-ray astronomy 610 $aopen science 610 $adata format 610 $amulti-messenger 610 $areal-time 610 $ahigh-energy 610 $aalerts 610 $avery-high-energy ?-ray astronomy 610 $aatmospheric Cherenkov telescopes 610 $asource catalogues 610 $agamma-ray astronomy 610 $aCherenkov telescopes 610 $aISM: supernova remnants 610 $aISM: individual objects-Crab Nebula 610 $apulsars: general 610 $aradiation mechanisms: nonthermal 610 $agamma rays: general 610 $aacceleration of particles 610 $aastrophysical plasmas 610 $aMHD 610 $ahigh-energy gamma-ray astrophysics 610 $aGamma-ray bursts 610 $anon-thermal emission 610 $aradiative processes 610 $avery-high energy Gamma-rays 610 $astatistical analysis 610 $alikelihood 610 $abayes 610 $aimaging atmospheric Cherenkov telescope 610 $aIACT 610 $aIACT technology 610 $avery high energy gamma-ray telescope 610 $aground-based gamma-ray astrophysics 615 7$aResearch & information: general 615 7$aMathematics & science 700 $ade Almeida$b Ulisses Barres$4edt$01307822 702 $aDoro$b Michele$4edt 702 $ade Almeida$b Ulisses Barres$4oth 702 $aDoro$b Michele$4oth 906 $aBOOK 912 $a9910639997503321 996 $aHigh-Energy Gamma-Ray Astronomy$93029034 997 $aUNINA LEADER 05130nam 2201237z- 450 001 9910595078103321 005 20220916 035 $a(CKB)5680000000080745 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92020 035 $a(oapen)doab92020 035 $a(EXLCZ)995680000000080745 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPrecision Medicine in Solid Tumors 210 $aBasel$d2022 215 $a1 online resource (304 p.) 311 08$a3-0365-4791-6 311 08$a3-0365-4792-4 330 $aIn the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. 606 $aMedicine and Nursing$2bicssc 606 $aOncology$2bicssc 610 $aadjuvant chemotherapy 610 $aanaplastic lymphoma receptor tyrosine kinase 610 $abreast cancer 610 $acancer 610 $acancer-associated fibroblasts 610 $acfDNA 610 $achemotherapy 610 $acirculating free DNA 610 $aclinical guideline 610 $aclonality classification 610 $acomprehensive genomic profiling 610 $aCTC 610 $actDNA 610 $aDDR genes 610 $aDecision tree 610 $adigital enrichment 610 $adriver mutation 610 $aEGFR mutation 610 $aEGFR-TKI 610 $aelectronic records 610 $aepidermal growth factor receptor 610 $aextent of resection 610 $agene panel sequencing 610 $aglioblastoma prognosis 610 $aHNSCC 610 $aimmune checkpoint inhibitors 610 $aimmunocytochemistry 610 $aimmunotherapy 610 $aintratumor heterogeneity 610 $alaboratory-friendly 610 $aliquid biopsy 610 $amolecular barcoding 610 $amolecular genotyping 610 $amultiple biopsies 610 $an/a 610 $anew drug development 610 $anext-generation sequencing 610 $anext-generation sequencing (NGS) 610 $aNGS 610 $anon-small cell lung cancer 610 $aopen data 610 $aosimertinib 610 $aoutcome 610 $aoverall survival 610 $aparallel double-detection 610 $aPARP inhibitors 610 $aPD-L1 610 $apediatric tumors 610 $apersonalized precision oncology 610 $aprecision medicine 610 $apresumed germline findings 610 $arandom forest 610 $aregulatory reform 610 $aresistance 610 $ascreening 610 $asequencing 610 $asmoking 610 $asolid cancer 610 $astrategic therapeutic intervention 610 $atargeted therapy 610 $atDNA 610 $athymoma 610 $aTMB 610 $aTNBC subtypes 610 $atriple-negative breast cancer (TNBC) 610 $atumor evolution 610 $atumor mutational burden 610 $atumor profiling test 610 $atyrosine kinase inhibitor 610 $auniversal health-care system 610 $awhole-exome sequencing 615 7$aMedicine and Nursing 615 7$aOncology 700 $aDey$b Nandini$4edt$01332329 702 $aDe$b Pradip$4edt 702 $aDey$b Nandini$4oth 702 $aDe$b Pradip$4oth 906 $aBOOK 912 $a9910595078103321 996 $aPrecision Medicine in Solid Tumors$93040843 997 $aUNINA